Eledon Pharmaceuticals (ELDN) Income from Continuing Operations (2013 - 2026)
Eledon Pharmaceuticals posted quarterly Income from Continuing Operations of 21181000.0 for Q1 2026, down 17.91% year-on-year from 25801551.77 in Q1 2025, and down 11.07% on a QoQ basis from 19070000.0 in Q3 2025.
Eledon Pharmaceuticals (ELDN) has 14 years of Income from Continuing Operations data on file, last reported at 21181000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 17.91% year-over-year to 21181000.0; the trailing twelve-month figure through Mar 2026 stood at 82948000.0 (down 468.02% YoY), and the FY2025 full-year result was 45617000.0, down 26.07% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 21181000.0, down from 19070000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 38373000.0 in Q4 2024 and bottomed at 58384000.0 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 11154000.0 (2023), against an average of 12680937.5.
- The widest annual swing landed in 2022, when Income from Continuing Operations tumbled 306.68%; it then soared 368.59% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 58384000.0 in 2022, then soared by 114.03% to 8189000.0 in 2023, then surged by 368.59% to 38373000.0 in 2024, then plunged by 149.7% to 19070000.0 in 2025, then slipped by 11.07% to 21181000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 21181000.0 (Q1 2026), 19070000.0 (Q3 2025), and 24733000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Eledon Pharmaceuticals | 419.90 Mn | 203.87 Mn | - | -21.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.18 Mn |
| Sep 30, 2025 | -19.07 Mn |
| Jun 30, 2025 | -24.73 Mn |
| Mar 31, 2025 | -17.96 Mn |
| Dec 31, 2024 | 38.37 Mn |
| Sep 30, 2024 | -20.51 Mn |
| Jun 30, 2024 | -14.50 Mn |
| Mar 31, 2024 | -10.87 Mn |
| Dec 31, 2023 | 8.19 Mn |
| Sep 30, 2023 | -11.20 Mn |
| Jun 30, 2023 | -10.35 Mn |
| Mar 31, 2023 | -11.11 Mn |
| Dec 31, 2022 | -58.38 Mn |
| Sep 30, 2022 | -10.47 Mn |
| Jun 30, 2022 | -9.25 Mn |
| Mar 31, 2022 | -9.86 Mn |
| Dec 31, 2021 | 28.25 Mn |
| Sep 30, 2021 | -9.82 Mn |
| Jun 30, 2021 | -7.38 Mn |
| Mar 31, 2021 | -8.50 Mn |
| Dec 31, 2020 | -6.50 Mn |
| Sep 30, 2020 | -6.14 Mn |
| Jun 30, 2020 | -2.59 Mn |
| Mar 31, 2020 | -8.18 Mn |
| Dec 31, 2019 | -4.17 Mn |
| Sep 30, 2019 | -2.92 Mn |
| Jun 30, 2019 | -4.09 Mn |
| Mar 31, 2019 | -4.88 Mn |
| Dec 31, 2018 | -4.58 Mn |
| Sep 30, 2018 | -3.50 Mn |
| Jun 30, 2018 | -3.19 Mn |
| Mar 31, 2018 | -2.80 Mn |
| Dec 31, 2017 | -2.11 Mn |
| Sep 30, 2017 | -2.97 Mn |
| Jun 30, 2017 | -6.67 Mn |
| Mar 31, 2017 | -1.36 Mn |
| Dec 31, 2016 | -3.74 Mn |
| Sep 30, 2016 | -1.58 Mn |
| Jun 30, 2016 | -883,000.00 |
| Mar 31, 2016 | -11.43 Mn |
| Dec 31, 2015 | -11.02 Mn |
| Sep 30, 2015 | -11.85 Mn |
| Jun 30, 2015 | -8.96 Mn |
| Mar 31, 2015 | -13.26 Mn |
| Dec 31, 2014 | -6.21 Mn |
| Sep 30, 2014 | -6.39 Mn |
| Jun 30, 2014 | -5.85 Mn |
| Mar 31, 2014 | -4.85 Mn |
| Dec 31, 2013 | -5.55 Mn |
| Sep 30, 2013 | -3.37 Mn |